ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsGB consults for SciNeuro and Lexeo, has consulted for AbbVie, E-Scape, Eisai, and Vida Ventures, and is on the scientific advisory board for Kisbee Therapeutics. All other authors declare no competing interests. Competing interests GB consults for SciNeuro and Lexeo, has consulted for AbbVie, E-Scape, Eisai, and Vida Ventures, and is on the scientific advisory board for Kisbee Therapeutics. All other authors declare no competing interests."

"Funding Work in authors’ laboratories related to this topic has been supported by BrightFocus foundation and a NIH grant R01AG062110 (C.-C.L.), a NIH grant U19AG069701 (to G.B., and C.-C.L.), NIH grants R37AG027924, and RF1AG057181 (to G.B.), and Cure Alzheimer’s Fund (to G.B.)."